| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2014-09-29 | RPL554 | cystic fibrosis |
Verona Pharma (UK) | Rare diseases - Genetic diseases | |
| 2014-09-29 | LiquiTime® Ibuprofen | 1 | Flamel Technologies (France) | CNS diseases | |
| 2014-09-29 | HIV vaccine candidate | HIV infection |
preclinical | Mymetics (Switzerland) | Infectious diseases |
| 2014-09-28 | Perjeta® (pertuzumab) | previously untreated HER2-positive metastatic breast cancer (mBC) |
3 | Roche (Switzerland) | Cancer - Oncology |
| 2014-09-27 | reslizumab | asthma | 3 | Teva Pharmaceutical Industries (Israel) | Allergic diseases - Inflammatory diseases - Respiratory diseases |
| 2014-09-27 | tasquinimod | advanced or metastatic hepato-cellular, ovarian, renal cell and gastric carcinomas in patients who have progressed after standard anti-tumor therapies |
2 | Ipsen (France) Active Biotech (Sweden) | Cancer - Oncology |
| 2014-09-27 | veliparib (ABT-888) | previously untreated metastatic or advanced non-small cell lung cancer (NSCLC) | 2 | Abbvie (USA - IL) | Cancer - Oncology |
| 2014-09-27 | Zykadia® (ceritinib) - LDK378 | anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) |
1 | Novartis (Switzerland) | Cancer - Oncology |
| 2014-09-26 | GSK2402968 (`968 - drisapersen) | Duchenne muscular dystrophy (DMD) |
3 | GSK (UK) Prosensa (The Netherlands) | Rare diseases - Neuromuscular diseases |
| 2014-09-26 | Keytruda® (pembrolizumab) and talimogene Laherparepvec | melanoma | 1b/3 | Amgen (USA - CA) Merck&Co (USA - NJ) | Cancer - Oncology |
| 2014-09-26 | olaptesed pegol (NOX-A12) | multiple myeloma | Noxxon Pharma (Germany) Dana Farber Cancer Institute (USA - MA) | Cancer - Oncology | |
| 2014-09-26 | elotuzumab (BMS-901608) in combination with either lirilumab (BMS-986015) or urelumab (BMS-663513) | multiple myeloma | 1 | BMS (USA - NY) | Cancer - Oncology |
| 2014-09-26 | rivipansel | vaso-occlusive crisis of sickle cell disease (VOC) |
3 | Pfizer (USA - NY) Glycomimetics (USA - MD) | Hematological diseases - Rare diseases |
| 2014-09-25 | Vesneo® (latanoprostene bunod (previously known as BOL-303259-X and NCX 116) ) | reduction of intraocular pressure (IOP) in patients with glaucoma or ocular hypertension |
3 | NicOx (France) Bausch&Lomb (USA) | Ophtalmological diseases |
| 2014-09-25 | CDX-301 (FMS-like tyrosine kinase-3 ligand or Flt3L) | mobilization and transplantation of allogeneic hematopoietic stem cells in patients with hematological malignancies undergoing hematopoietic stem cell transplantation |
Celldex Therapeutics (USA - NJ) | Transplantation - Cancer - Oncology | |
| 2014-09-24 | semi-automated image analysis method | Duchenne muscular dystrophy (DMD) Becker\'s muscular dystrophy (BMD) |
Prosensa (The Netherlands) | Rare diseases - Neuromuscular diseases | |
| 2014-09-24 | cardiac amyloidosis |
Alnylam Pharmaceuticals (USA - MA) | Rare diseases - Genetic diseases - Cardiovascular diseases | ||
| 2014-09-24 | BJI InoPlex™ test | hip and knee replacement infections |
Diaxonhit (France) | Infectious diseases - Diagnostic | |
| 2014-09-23 | Rayaldee™ ( calcifediol - vitamin D prohormone) | secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency |
3 | OPKO Health (USA - FL) | Endocrine diseases - Hormonal diseases- Kidney diseases - Renal diseases |
| 2014-09-23 | CNV1014802 | pain associated with lumbosacral radiculopathy (sciatica) |
2 | Convergence Pharmaceuticals | CNS diseases |
